Skip to search formSkip to main contentSkip to account menu

Reditux

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
using the results of the studies. In DLBCL patients, VSS and T1⁄2 − β of RedituxTM are about 80 % lower than what was reported… 
2015
2015
مقايسه اثرات درماني وعوارض ريتوکسيماب داخلي (Reditux) بامشابه تجاري آن (MabThera) دربيماران مبتلابه لنفوم منتشرسلول بزرگ DLBCL)B… 
2014
2014
Background: Rituximab is a chimeric IgG1 monoclonal antibody targeting the CD20 surface antigen on normal and neoplastic B cells… 
2011
2011
volume 29 number 3 mArCH 2011 nature biotechnology With Rituxan’s patents facing expiration, the drug has become a prime target… 
2011
2011
volume 29 number 3 mArCH 2011 nature biotechnology With Rituxan’s patents facing expiration, the drug has become a prime target…